ABSTRACT
Autoimmune diseases of the nervous system are a group of diseases caused by the body′s immune system attacking its own nervous system, resulting in structural damage and functional impairment of the corresponding tissues. Interventional clearance of pathogenic auto-antibodies has been shown to be effective in reducing immune damage, inhibiting disease progression and improving prognosis through extensive basic research and long-term clinical practice. The neonatal Fc receptor (FcRn)-mediated circulating protection mechanism of IgG contributes to the long half-life and high plasma levels of IgG. FcRn inhibitors are able to target and block the binding of FcRn to IgG, accelerating IgG clearance and reducing IgG levels. Therefore, the use of FcRn inhibitors in the treatment of autoimmune diseases of the nervous system could theoretically help to accelerate the clearance of pathogenic IgG, achieve good clinical efficacy and have promising applications. Research in this area has made considerable progress in recent years and this article will review this.
ABSTRACT
The febrile respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the focus of global attention. Up to now, the infection has been continuing to spread all over the world and it is urgent to develop specific drugs for SARS-CoV-2. Finding effective and safe drugs which are already available in the market for treating coronavirus disease 2019 (COVID-19) is one of the main strategies to solve the problem in time. As quinoline alkaloids against malaria, chloroquine and hydroxychloroquine have been proved to have the anti-SARS-CoV-2 activity. Quinoline alkaloids are expected to be important drugs for the treatment of COVID-19. In this article, the research and application of chloroquine and hydroxychloroquine are reviewed from the aspects of pharmacokinetics, drug interaction, clinical research progress, treatment plan optimization and resolution of optical enantiomers. The possible problems are summarized in order to provide reference for further research and clinical application of quinoline alkaloids in the treatment of COVID-19.